Phase II AIDS Malignancy Consortium Trial of Topical Halofuginone in AIDS-Related Kaposi Sarcoma
Henry Koon(Case Western Reserve University), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Jeannette Y. Lee(University of Arkansas at Little Rock), Barbara Fingleton(Vanderbilt University), David M. Aboulafia(Virginia Mason Medical Center), Robert A. Parise(Beth Israel Deaconess Medical Center), Bruce J. Dezube(Xilio Therapeutics (United States)), Julia T. Geyer(Cornell University), Merrill J. Egorin(Beth Israel Deaconess Medical Center), Ethel Cesarman(Cornell University)
Cited by 60
Related Papers
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
|Science|2002|2.7k
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
|Journal of Clinical Oncology|2000|1.6k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707